Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. ( AXSM ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Darren Opland - Director of Corporate Communications Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Ari Maizel - Chief Commercial Officer Mark Jacobson - Chief Operating Officer Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Sean Laaman - Morgan Stanley, Research Division Ashwani Verma - UBS Investment Bank, Research Division Lin Tsai - Jefferies LLC, Research Division Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Joon Lee - Truist Securities, Inc., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Dina Ramadane - BofA Securities, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division David Hoang - Deutsche Bank AG, Research Division Troy Langford - TD Cowen, Research Division Myles Minter - William Blair & Company L.L.C.
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating
Axsome Therapeutics is transitioning into a leading neuroscience company with three marketed drugs and a robust late-stage pipeline. Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi, with improving margins and narrowing net losses. AXSM faces risks from competition, regulatory hurdles, and high valuation, but maintains strong cash reserves and disciplined expense control.
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Asim Rana - Truist Securities, Inc., Research Division David A. Amsellem - Piper Sandler & Co., Research Division David Timothy Hoang - Deutsche Bank AG, Research Division Graig C.
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
